One Can’t even MAKE THIS UP Oppenheimer Update $AMRN Stopping of STRENGTH May Weaken Vascepa's Commercial Outlook; Reiterate Underperform $AZN appears to have no plans to ever launch Epanova Removal of Epanova from our $AMRN model leads us to #increase our price target to $13 (vs. prior $8).
Market Data 
Markets 
AI
